These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 15470328

  • 1. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T.
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
    Hu YM, Xu JM, Mei Q, Xu XH, Xu SY.
    Acta Pharmacol Sin; 2005 Mar; 26(3):384-8. PubMed ID: 15715938
    [Abstract] [Full Text] [Related]

  • 7. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
    Shimatani T, Inoue M, Kuroiwa T, Horikawa Y.
    Aliment Pharmacol Ther; 2004 Jan 01; 19(1):113-22. PubMed ID: 14687173
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
    Hu YM, Mei Q, Xu XH, Hu XP, Hu NZ, Xu JM.
    World J Gastroenterol; 2006 Aug 07; 12(29):4750-3. PubMed ID: 16937451
    [Abstract] [Full Text] [Related]

  • 9. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T.
    Clin Pharmacol Ther; 2006 Nov 07; 80(5):539-48. PubMed ID: 17112810
    [Abstract] [Full Text] [Related]

  • 10. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R.
    Gastroenterology; 2000 Sep 07; 119(3):670-6. PubMed ID: 10982760
    [Abstract] [Full Text] [Related]

  • 11. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
    Hayato S, Hasegawa S, Hojo S, Okawa H, Abe H, Sugisaki N, Munesue M, Horai Y, Ohnishi A.
    Eur J Clin Pharmacol; 2012 May 07; 68(5):579-88. PubMed ID: 22108775
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T.
    Br J Clin Pharmacol; 2006 Mar 07; 61(3):309-14. PubMed ID: 16487224
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB, Park SJ, Ryu JK, Lee JK, Kim HJ, Bae JS, Jung HS, Park SM.
    Korean J Gastroenterol; 2003 Dec 07; 42(6):468-75. PubMed ID: 14695703
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct 07; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M, Togawa J, Takahashi K, Yoneda M, Fujisawa N, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H.
    J Gastroenterol Hepatol; 2003 Sep 07; 18(9):1034-8. PubMed ID: 12911659
    [Abstract] [Full Text] [Related]

  • 18. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
    Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T.
    Aliment Pharmacol Ther; 2001 Dec 07; 15(12):1929-37. PubMed ID: 11736724
    [Abstract] [Full Text] [Related]

  • 19. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2001 Nov 07; 70(5):484-92. PubMed ID: 11719736
    [Abstract] [Full Text] [Related]

  • 20. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
    Miura M, Kagaya H, Tada H, Uno T, Yasui-Furukori N, Tateishi T, Suzuki T.
    Br J Clin Pharmacol; 2006 Mar 07; 61(3):315-20. PubMed ID: 16487225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.